Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

Science

Volumn 288, Issue 5466, 2000, Pages 669-672

  Cavazzana Calvo, Marina ^a   Hacein Bey, Salima ^a   De Saint Basile, Geneviève ^a   Gross, Fabian ^a   Yvon, Eric ^a   Nusbaum, Patrick ^a   Selz, Françoise ^a   Hue, Christophe ^a   Certain, Stéphanie ^a   Casanova, Jean Laurent ^a   Bousso, Philippe ^b   Le Deist, Françoise ^a   Fischer, Alain ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CASE REPORT; COMBINED IMMUNODEFICIENCY; GENE THERAPY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT INDICATION;

ANTIGENS, CD34; B-LYMPHOCYTES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOGLOBULINS; INFANT; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MOLONEY MURINE LEUKEMIA VIRUS; MUTATION; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, INTERLEUKIN; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TRANSGENES;

UNIDENTIFIED RETROVIRUS;

EID: 0034724857     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.288.5466.669     Document Type: Article

References (33)

1. M. Noguchi et al., Cell 73, 147 (1993).
2. K. Sugamura et al., Annu. Rev. Immunol. 14, 179 (1996).
3. W. J. Leonard. Annu. Rev. Med. 47, 229 (1996).
4. R. H. Buckley et al., N. Engl. J. Med. 340, 508 (1999).
5. S. Hacein-Bey et al., Blood 87, 3108 (1996).
6. F. Candotti et al., Blood 87, 3097 (1996).
7. N. Taylor et al., Blood 87, 3103 (1996).
8. M. Cavazzana-Calvo et al., Blood 88, 3901 (1996).
9. S. Hacein-Bey et al., Blood 92, 4090 (1998).
10. M. Lo et al., Blood 94, 3027 (1999).
11. C. Soudais et al., Blood 95, 3071 (2000).
12. T. Whitwam et al., Blood 92, 1565 (1998).
13. V. Stephan et al., N Engl. J. Med. 335, 1563 (1996).
14. P. Bousso et al., Proc. Natl. Acad. Sci. U.S.A. 97, 274 (2000).
15. Patient 1 had pneumocystis carinii pneumonitis and had received BCG immunization. Patient 2 suffered from recurrent oral candidiasis, pneumocystis carinii infection, protracted diarrhea, failure to thrive, and GVHD-like skin lesions. Neither patient had an HLA (human leukocyte antigen)-identical sibling. Patients were placed in a sterile isolation ward and received nonabsorbable oral antibiotics and intravenous Igs every 3 weeks for 3 months. Parents gave informed consent for participation in the trial.
16. 2. Containers were precoated with the CH296 human fragment of fibronectin (50 μg/ml) (TaKaRa, Shiga, Japan). Retroviral containing supernatant was added every day for 3 days. Cells were then harvested, washed twice, and infused back into the patients.
17. 2. Containers were precoated with the CH296 human fragment of fibronectin (50 μg/ml) (TaKaRa, Shiga, Japan). Retroviral containing supernatant was added every day for 3 days. Cells were then harvested, washed twice, and infused back into the patients.
18. For semiquantitative PCR and RT-PCR analysis, DNA was isolated from the indicated cell populations. A reference standard curve was constructed by diluting cells from a SCID-X1-derived Epstein-Barr virus (EBV)-B cell line containing one copy per cell of the MFG γc provirus (5) in uninfected cells from the same EBV-B cell line (100, 10, 1, 0.1, 0.01, and 0.001%). DNA from each sample was also quantified by actin gel amplification. MFG γc primers sequences and actin primers sequences are available on request. DNA was amplified in a 50 μl of PCR reaction mixture by using 30 cycles at an annealing temperature of 60°, for γc primers and 68°C for actin primers. A sample of the amplified product was separated on a 1% agarose gel and analyzed by ethidium bromide staining. RNA was prepared with the RNA easy kit (Qiagen) and was reverse-transcribed with the Superscript Preamplification System (Gibco-BRL). γc proviral and β-actin cDNA amplification were performed as described above. Quantification of expression was made by comparison with RNA isolated from the same standard curve of diluted cells.
19. M. Cavazzana-Calvo et al., data not shown.
20. The following monoclonal antibodies (mAbs) were used in immunofluorescence studies: anti-γc chain: Tugh 4 (rat IgG2, PharMingen, San Diego, CA); anti-CD3: Leu 4 (IgG2a, Becton Dickinson, San Diego, CA); anti-CD4: Leu3a (IgG1, Becton Dickinson); anti-CD8: Leu 2a (IgG1, Becton Dickinson); anti-CD19: J4 119 (IgG1 Immunotech, Marseille, France); anti-CD14: Leu M3 (Becton Dickinson); anti-CD16: 3G8 (IgG1, Immunotech); anti-CD56: MY31 (IgG1, Becton Dickinson); anti-CD15 (IgM, PharMingen); anti-TCR αβ: BMA031 (IgG1, Immunotech); anti-TCR γδ: IMMU 515 (IgG1, Immunotech); anti-CD45RO: UCHL1 (IgG2a, Immunotech); anti-CD45RA: 2H4 (IgG1, Coulter Clone, Margency, France); anti-CD34: HPCA-2 (IgG1, Becton Dickinson); anti-TcR Vβ2: MPB2D5 (IgG1, Immunotech); anti-TcR Vβ3: CH92 (IgM, Immunotech); anti-TcR Vβ5.1: IMMU 157 (IgG2a, Immunotech); anti-TcR Vβ5.2: 36213 (IgG1, Immunotech); anti-TcR Vβ5.3: 3D11 (IgG1, Immunotech); anti-TcR Vβ8: 56C5.2 (IgG2a, Immunotech); anti-TcR Vβ9: FIN9 (IgG2a, Immunotech); anti-TcR Vβ13.1: IMMU 222 (IgG2, Immunotech); anti-TcR Vβ13.6: JU74.3 (IgG1, Immunotech); anti-TcR Vβ14: CAS1.13 (IgG1, Immunotech); anti-TcR Vβ17: E17.5F3.15.13 (IgG1, Immunotech); anti-TcR Vβ21.3: IG125 (IgG2, Immunotech). Fluorescence staining was done with phycoerythrin- or fluorescein isothiocyanate - conjugated mAbs. Cells were analyzed on a FACScan flow cytometer (Becton Dickinson).
21. C. Pannetier et al., Proc. Natl. Acad. Sci. U.S.A. 90, 4319 (1993).
22. Unstimulated lymphocyte proliferations were <1000 cpm. Control positive values of antigen-stimulated proliferations were > 10,000 cpm.
23. This patient was treated at 1 month of age. Within 3 months, T and NK lymphocyte counts reached age-matched control values. The γc expression at T and NK cell surfaces was fully restored. The child is at home without any therapy, 4 months after treatment.
24. C. Bordignon, Nature Med. 4, 19 (1998).
25. C. Bordignon et al., Science 270, 470 (1995).
26. D. B. Kohn et al., Nature Med. 1, 1017 (1995).
27. D. B. Kohn et al., Nature Med. 4, 775 (1998).
28. V. W. Van Beusechem et al., Gene Ther. 3, 179 (1996).
29. H. Hannenberg et al., Nature Med. 2, 876 (1996).
30. A. Fischer and B. Malissen, Science 280, 237 (1998).
31. M. Kondo, I. L. Weissman, K. Akashi, Cell 9, 661 (1997).
32. P. B. Robbins et al., Proc. Natl. Acad. Sci. U.S.A. 95, 10182 (1998).
33. We thank the medical and nursing staff of the Unité d'Immunologie et d'Hématologie pédiatriques, Hôpital des Enfants-Malades, for patient care. We also thank C. Harré and C. Jacques for technical help; D. Bresson for preparation of the manuscript; N. Wulfraat for patient referral; O. Danos, M. Fougereau, P. Mannoni, C. Eaves, and L. Coulombel for advice; A. Gennery for assistance with English translation; B. Bussière, C. Cailliot, and J. Caraux (Amgen, France) for providing SCF and MGDF; J. Bender and D. Van Epps (Nexell Therapeutics, Irvine, CA) for providing containers, and S. Yoshimura and I. Kato (Takara Shuzo, Shiga, Japan) for providing the CH-296 fibronectin fragment. Supported by grants from INSERM, Association Française des Myopathies, Agence Française du Sang, and the Programme Hospitalier de Recherche Clinique (Health Ministry).